{"pmid":32296259,"pmcid":"PMC7158785","title":"Convalescent plasma: A possible treatment of COVID-19 in India.","text":["Convalescent plasma: A possible treatment of COVID-19 in India.","In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection.","Med J Armed Forces India","Teixeira da Silva, Jaime A","32296259"],"abstract":["In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection."],"journal":"Med J Armed Forces India","authors":["Teixeira da Silva, Jaime A"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296259","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.mjafi.2020.04.006","keywords":["Antibodies","Asia","Respiratory disease","SARS-CoV-2 virus"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["India","USA","Italy","Spain","India","Indian","China","India"],"countries":["Italy","India","Spain","China","United States"],"countries_codes":["ITA|Italy","IND|India","ESP|Spain","CHN|China","USA|United States"],"_version_":1664266651141406721,"score":8.233237,"similar":[{"pmid":32254064,"title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19.","text":["Deployment of convalescent plasma for the prevention and treatment of COVID-19.","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. .","J Clin Invest","Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar","32254064"],"abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. ."],"journal":"J Clin Invest","authors":["Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32254064","week":"202015|Apr 06 - Apr 12","doi":"10.1172/JCI138745","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1663450393494945792,"score":354.5594},{"pmid":32253318,"title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients.","text":["Effectiveness of convalescent plasma therapy in severe COVID-19 patients.","Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 x 10(9)/L vs. 0.76 x 10(9)/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.","Proc Natl Acad Sci U S A","Duan, Kai","Liu, Bende","Li, Cesheng","Zhang, Huajun","Yu, Ting","Qu, Jieming","Zhou, Min","Chen, Li","Meng, Shengli","Hu, Yong","Peng, Cheng","Yuan, Mingchao","Huang, Jinyan","Wang, Zejun","Yu, Jianhong","Gao, Xiaoxiao","Wang, Dan","Yu, Xiaoqi","Li, Li","Zhang, Jiayou","Wu, Xiao","Li, Bei","Xu, Yanping","Chen, Wei","Peng, Yan","Hu, Yeqin","Lin, Lianzhen","Liu, Xuefei","Huang, Shihe","Zhou, Zhijun","Zhang, Lianghao","Wang, Yue","Zhang, Zhi","Deng, Kun","Xia, Zhiwu","Gong, Qin","Zhang, Wei","Zheng, Xiaobei","Liu, Ying","Yang, Huichuan","Zhou, Dongbo","Yu, Ding","Hou, Jifeng","Shi, Zhengli","Chen, Saijuan","Chen, Zhu","Zhang, Xinxin","Yang, Xiaoming","32253318"],"abstract":["Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 x 10(9)/L vs. 0.76 x 10(9)/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials."],"journal":"Proc Natl Acad Sci U S A","authors":["Duan, Kai","Liu, Bende","Li, Cesheng","Zhang, Huajun","Yu, Ting","Qu, Jieming","Zhou, Min","Chen, Li","Meng, Shengli","Hu, Yong","Peng, Cheng","Yuan, Mingchao","Huang, Jinyan","Wang, Zejun","Yu, Jianhong","Gao, Xiaoxiao","Wang, Dan","Yu, Xiaoqi","Li, Li","Zhang, Jiayou","Wu, Xiao","Li, Bei","Xu, Yanping","Chen, Wei","Peng, Yan","Hu, Yeqin","Lin, Lianzhen","Liu, Xuefei","Huang, Shihe","Zhou, Zhijun","Zhang, Lianghao","Wang, Yue","Zhang, Zhi","Deng, Kun","Xia, Zhiwu","Gong, Qin","Zhang, Wei","Zheng, Xiaobei","Liu, Ying","Yang, Huichuan","Zhou, Dongbo","Yu, Ding","Hou, Jifeng","Shi, Zhengli","Chen, Saijuan","Chen, Zhu","Zhang, Xinxin","Yang, Xiaoming"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253318","week":"202015|Apr 06 - Apr 12","doi":"10.1073/pnas.2004168117","keywords":["COVID-19","convalescent plasma","pilot project","treatment outcome"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663450393552617472,"score":333.91663},{"pmid":32240549,"title":"Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases.","text":["Pivotal Role of Convalescent Plasma in Managing Emerging Infectious Diseases.","Infectious diseases remain one of the top 10 global health threats as announced by the World Health Organization [1]. The emergence of new pathogens for which there is no effective treatment has redrawn the attention to the usefulness of convalescent plasma. Indeed, convalescent plasma can be an alternate and fast therapeutic option in outbreaks of infectious diseases such as Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS), Chikungunya, Ebola and Zika [2-4]. The recent Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has prompted not only a search for effective anti-viral treatment and spread control measures, but also a reconsideration of the use of convalescent plasma for COVID-19 treatment [5, 6].","Vox Sang","Wong, H K","Lee, C K","32240549"],"abstract":["Infectious diseases remain one of the top 10 global health threats as announced by the World Health Organization [1]. The emergence of new pathogens for which there is no effective treatment has redrawn the attention to the usefulness of convalescent plasma. Indeed, convalescent plasma can be an alternate and fast therapeutic option in outbreaks of infectious diseases such as Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS), Chikungunya, Ebola and Zika [2-4]. The recent Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has prompted not only a search for effective anti-viral treatment and spread control measures, but also a reconsideration of the use of convalescent plasma for COVID-19 treatment [5, 6]."],"journal":"Vox Sang","authors":["Wong, H K","Lee, C K"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240549","week":"202014|Mar 30 - Apr 05","doi":"10.1111/vox.12927","keywords":["COVID-19","SARS-CoV-2","blood center","convalescent plasma","emerging infection"],"source":"PubMed","locations":["Ebola","Chikungunya","Zika"],"topics":["Treatment"],"weight":1,"_version_":1663352135515897858,"score":276.9451},{"pmid":32293713,"title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.","text":["Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.","The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis. This article is protected by copyright. All rights reserved.","J Med Virol","Ye, Mingxiang","Fu, Dian","Ren, Yi","Wang, Faxiang","Wang, Dong","Zhang, Fang","Xia, Xinyi","Lv, Tangfeng","32293713"],"abstract":["The discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the outbreak of coronavirus disease 2019 (COVID-19) are causing public health emergency. A handful of literatures have summarized its clinical and radiologic features, whereas therapies for COVID-19 are rather limited. In order to evaluate the efficacy of convalescent plasma therapy in COVID-19 patients, we did this timely descriptive study. 6 laboratory confirmed COVID-19 patients were enrolled and received the transfusion of ABO-compatible convalescent plasma. The efficacy of this intervention was determined by the alleviation of symptoms, changes in radiologic abnormalities and laboratory tests. No obvious adverse effect observed during the treatment. Transfusion of convalescent plasma led to a resolution of ground glass opacities (GGOs) and consolidation in patient #1, #2, #3, #4 and #6. In patient #1 and #5 who presented with SARS-CoV-2 in throat swab, convalescent plasma therapy elicited an elimination of virus. Serologic analysis indicated an immediate increase in anti-SARS-CoV-2 antibody titers in patient #2 and #3, but not in patient #1. This study indicates that convalescent plasma therapy is effective and specific for COVID-19. This intervention has a special significance for eliminating SARS-CoV-2 and is believed to be a promising state-of-art therapy during COVID-19 pandemic crisis. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Ye, Mingxiang","Fu, Dian","Ren, Yi","Wang, Faxiang","Wang, Dong","Zhang, Fang","Xia, Xinyi","Lv, Tangfeng"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293713","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25882","keywords":["COVID-19","SARS-CoV-2","convalescent plasma therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266295586062336,"score":254.41644},{"pmid":32259313,"title":"Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.","text":["Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.","The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.","Pharmacotherapy","Barlow, Ashley","Landolf, Kaitlin M","Barlow, Brooke","Yeung, Siu Yan Amy","Heavner, Jason J","Claassen, Cassidy W","Heavner, Mojdeh S","32259313"],"abstract":["The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit (ICU) admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacological management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immune modulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic."],"journal":"Pharmacotherapy","authors":["Barlow, Ashley","Landolf, Kaitlin M","Barlow, Brooke","Yeung, Siu Yan Amy","Heavner, Jason J","Claassen, Cassidy W","Heavner, Mojdeh S"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259313","week":"202015|Apr 06 - Apr 12","doi":"10.1002/phar.2398","keywords":["Antivirals","Critical care","Cytochrome P450","Dialysis","Infectious disease","Liver","Pharmacokinetics","Pharmacology","Renal"],"source":"PubMed","locations":["vivo"],"topics":["Treatment"],"weight":1,"_version_":1663450393445662720,"score":240.06735}]}